跳至主要内容
临床试验/2025-524761-25-00
2025-524761-25-00招募中4 期

The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial

Santiago Dexeus Font Fundacio Privada4 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2026年4月15日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
240
试验地点
4

研究概览

简要总结

To compare the number of good quality blastocysts based on the Istanbul consensus workshop criteria (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Hum Reprod 2011) in two stimulation groups with 10 mcg/day of follitropin delta (equivalent to 150 IU of rFSH) + 150 IU/day of hMG vs 5 mcg/day of follitropin delta (equivalent to 75 IU of rFSH) + 225 IU/day of hMG in advanced age women undergoing PGT-A with a PPOS protocol.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Infertile patients with indication for IVF
  • Undergoing preimplantation genetic screening cycles
  • Age ≥38 and <42 years old
  • AMH 0.5 – 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid)
  • BMI 18.5 – 30 Kg/m2
  • Normal karyotypes in both partners

排除标准

  • Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria
  • Severe male factor requiring TESE (testicular sperm extraction)
  • Administration of any other drug potentially interfering with the treatment
  • Contraindication for hormonal treatment
  • Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment)
  • Monogenic disease to be detected with PGT-M
  • Biochemical and/or ultrasonographic evidence of polycystic ovarian syndrome
  • Endocrinological and/or autoimmune disorders

研究者

发起方
Santiago Dexeus Font Fundacio Privada
申办方类型
Laboratory/Research/Testing facility
责任方
Principal Investigator
主要研究者

Ignacio Rodríguez

Scientific

Santiago Dexeus Font Fundacio Privada

研究点 (4)

Loading locations...

相似试验